Risk analysis and seroprevalence of bovine ephemeral fever virus in Punjab, Pakistan.

Bovine ephemeral fever (BEF) is a vector-borne viral disease caused by the RNA virus which belongs to the genus Ephemerovirus and the family Rhabdoviridae. To evaluate the effect of the risk factors like the breed of cattle and buffaloes, age, sex, lactation, housing and region on the bovine ephemeral fever virus (BEFV) prevalence, ELISA and virus neutralisation (VN) tests (n = 600) were performed for the BEFV prevalence. The seroprevalence in cattle was 45.6% and 42% by ELISA and VN, respectively (P = 0.001). The breed-wise seropositive ratio was (55-64%) in cattle and (22.5-18.3%) in buffaloes by VN and ELISA. The sex-wise prevalence was (40-49.4%) in females and (35.8-46%) in males by VN and ELISA in cattle and a similar prevalence was reported in buffaloes. The age-wise prevalence in bovines by ELISA was 5.33, 22.66 and 17.66% in the age group < 1 year, 1-3 years and > 3 years, respectively. The disease prevalence was higher in the age group of 1-3 years. The prevalence was higher during the 3rd lactation in bovines. The region-wise prevalence was higher in the 07 districts while lower (18-21%) in Rawalpindi District by VN and ELISA, respectively (P = 0.001). Commercial dairy farms of cattle showed a higher disease prevalence (52% and 44%) than non-commercial farms (38% and 36%) by ELISA and VN, respectively (P = 0.227). Exotic cows showed higher disease prevalence (76.67% and 70%) by ELISA and VN. The mortality in bovines was 5% (7.7% and 2.3%) in the cattle and buffaloes. The case fatality of BEFV in bovines was 12.25%. There was a significant effect of the risk factors like the breed, age, sex, lactation, housing and region on the BEFV prevalence. This is the first comprehensive study of BEFV in Pakistan.

Humoral immune response after different SARS-CoV-2 vaccination regimens.

BACKGROUND: The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2). METHODS: Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-neutralising antibodies (VNA) with three IgG assays based on (parts of) the SARS-CoV-2 spike (S)-protein as antigen, an IgG immunoblot (additionally contains the SARS-CoV-2 nucleoprotein (NP) as an antigen), a surrogate neutralisation test (sVNT), and a Vero-cell-based virus-neutralisation test (cVNT) with the B.1.1.7 variant of concern (VOC; alpha) as antigen. Investigation was done before and after heterologous (n = 30 and 42) or homologous booster vaccination (AZD1222/AZD1222, n = 8/9; BNT162b2/BNT162b2, n = 8/8). After the second immunisation, a subgroup of 26 age- and gender-matched sera (AZD1222/mRNA, n = 9; AZD1222/AZD1222, n = 9; BNT162b2/BNT162b2, n = 8) was also tested for VNA against VOC B.1.617.2 (delta) in the cVNT. The strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity. RESULTS: After the first vaccination, the prevalence of IgG directed against the (trimeric) SARS-CoV-2 S-protein and its receptor binding domain (RBD) varied from 55-95% (AZD1222) to 100% (BNT162b2), depending on the vaccine regimen and the SARS-CoV-2 antigen used. The booster vaccination resulted in 100% seroconversion and the occurrence of highly avid IgG, which is directed against the S-protein subunit 1 and the RBD, as well as VNA against VOC B.1.1.7, while anti-NP IgGs were not detected. The results of the three anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this VOC. The agreement of cVNT and sVNT results was good. However, the sVNT seems to overestimate non- and weak B.1.1.7-neutralising titres. The anti-SARS-CoV-2 IgG concentrations and the B.1.1.7-neutralising titres were significantly higher after heterologous vaccination compared to the homologous AZD1222 scheme. If VOC B.1.617.2 was used as antigen, significantly lower VNA titres were measured in the cVNT, and three (33.3%) vector vaccine recipients had a VNA titre < 1:10. CONCLUSIONS: Heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-SARS-CoV-2 IgG concentrations and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination scheme. Irrespective of the chosen immunisation regime, highly avid IgG antibodies can be detected just 2 weeks after the second vaccine dose indicating the development of a robust humoral immunity. The reduction in the VNA titre against VOC B.1.617.2 observed in the subgroup of 26 individuals is remarkable and confirms the immune escape of the delta variant.

Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2.

A number of seroassays are available for SARS-CoV-2 testing; yet, head-to-head evaluations of different testing principles are limited, especially using raw values rather than categorical data. In addition, identifying correlates of protection is of utmost importance, and comparisons of available testing systems with functional assays, such as direct viral neutralisation, are needed.We analysed 6658 samples consisting of true-positives (n=193), true-negatives (n=1091), and specimens of unknown status (n=5374). For primary testing, we used Euroimmun-Anti-SARS-CoV-2-ELISA-IgA/IgG and Roche-Elecsys-Anti-SARS-CoV-2. Subsequently virus-neutralisation, GeneScriptcPass, VIRAMED-SARS-CoV-2-ViraChip, and Mikrogen-recomLine-SARS-CoV-2-IgG were applied for confirmatory testing. Statistical modelling generated optimised assay cut-off thresholds. Sensitivity of Euroimmun-anti-S1-IgA was 64.8%, specificity 93.3% (manufacturer's cut-off); for Euroimmun-anti-S1-IgG, sensitivity was 77.2/79.8% (manufacturer's/optimised cut-offs), specificity 98.0/97.8%; Roche-anti-N sensitivity was 85.5/88.6%, specificity 99.8/99.7%. In true-positives, mean and median Euroimmun-anti-S1-IgA and -IgG titres decreased 30/90 days after RT-PCR-positivity, Roche-anti-N titres decreased significantly later. Virus-neutralisation was 80.6% sensitive, 100.0% specific (≥1:5 dilution). Neutralisation surrogate tests (GeneScriptcPass, Mikrogen-recomLine-RBD) were >94.9% sensitive and >98.1% specific. Optimised cut-offs improved test performances of several tests. Confirmatory testing with virus-neutralisation might be complemented with GeneScriptcPassTM or recomLine-RBD for certain applications. Head-to-head comparisons given here aim to contribute to the refinement of testing strategies for individual and public health use.

Serological evidence for exposure to bovine viral diarrhoea virus in sheep co-grazed with beef cattle in New Zealand.

Aims: To determine whether sheep that co-grazed with cattle that were suspected to be positive for bovine viral diarrhoea (BVD) virus had serological evidence of exposure to the virus.Methods: Eighteen commercial farms that routinely co-grazed cattle and sheep in the same paddocks were recruited through purposive sampling. The recruiting veterinarians identified nine farms with cattle herds that were known or highly suspected to be positive for BVD and nine farms that were considered to be free of BVD. Blood samples were taken from 15 ewes aged 1 year on each farm and samples were submitted to a commercial diagnostic laboratory to test for antibodies against pestiviruses using an ELISA. All samples that were positive were then tested using a virus neutralisation test (VNT)for antibodies against BVD virus.Results: Of the 270 blood samples, 17 were positive for pestivirus antibodies by ELISA and these originated from two farms that were known or suspected to have BVD virus-positive cattle. None of the samples from the nine flocks co-grazed with cattle herds that were known or suspected to be BVD virus-negative were positive for pestivirus antibodies. Within the two positive farms, 2/15 samples from the first farm and 15/15 samples from the second farm were antibody-positive. When the 17 positive blood samples were submitted for VNT, all 15 samples from the second farm tested positive for BVD virus antibodies with the highest titre being 1:512.Conclusions and clinical relevance: In this small sample of New Zealand sheep and beef farms with suspected BVD infection in cattle, there was evidence of pestivirus exposure in co-grazed sheep. Although we were unable to confirm the origin of the exposure in these sheep, these findings highlight that farmers who are trying to eradicate BVD from their cattle should be mindful that the infection may also be circulating in sheep, and both populations should be considered a possible risk to each other for generating transient and persistent infections. Further work is needed to estimate the true prevalence of New Zealand sheep flocks that are affected by BVD and the associated economic impacts.

Schmallenberg virus neutralising antibody responses in sheep.

BACKGROUND: Schmallenberg virus (SBV) is a midge borne virus of cattle and sheep. Infection is typically asymptomatic in adult sheep but fetal infection during pregnancy can result in abortion, stillbirth, neurological disorders and malformations of variable severity in newborn animals. It was first identified in Germany and the Netherlands in 2011 and then circulated throughout Europe in 2012 and 2013. Circulation in subsequent years was low or non-existent until summer and autumn 2016, leading to an increased incidence of deformed newborn lambs and calves in 2016-17. This study reports SBV circulation in October 2016 within a group of 24 ewes and 13 rams. The ewes were monitored at 3 times points over an 11 week period (September to December 2016). RESULTS: Most ewes displayed an increase in SBV VNT with antibody titre increases greater in older, previously exposed ewes. Two ewes had SBV RNA detectable by RT-qPCR, one on 30/09/16 and one on 04/11/16. Of these ewes, one had detectable serum SBV RNA (indicating viraemia) despite pre-existing antibody. The rams had been previously vaccinated with a commercial inactivated SBV vaccine, they showed minimal neutralising antibody titres against SBV 8 months post-vaccination and all displayed increased titre in October 2016. CONCLUSION: This data suggests that SBV circulated for a minimum period of 5 weeks in September to October 2016 in central England. Ewes previously exposed to virus showed an enhanced antibody response compared to naïve animals. Pre-existing antibody titre did not prevent re-infection in at least one animal, implying immunity to SBV upon natural exposure may not be life-long. In addition, data suggests that immunity provided by killed adjuvanted SBV vaccines only provides short term protection (< 8 months) from virus.

Mutations in foot and mouth disease virus types A and O isolated from vaccinated animals.

Foot and mouth disease (FMD) is responsible for serious economic losses in Egypt. Although vaccination is practised as the main control strategy, failure of vaccination has been reported in many cases, which can be due to a number of factors. Selection of FMD antigenic variants under the immune pressure of partially immunised hosts has been previously recorded. This study was designed to isolate and characterise foot and mouth disease viruses (FMDVs) circulating in Egyptian vaccinated animals. Serotype O, A and Southern African Territories (SAT) 2 FMDVs were detected in different Egyptian governorates during 2015, 2016 and 2017. The successful isolation of 15 FMDVs of the three serotypes is reported in this paper. Phylogenetic analysis based on the viral protein (VP) 1 gene showed that all serotype O isolates had East Africa (EA)-3 topotypes. There was variation in 15-17 amino acids between the serotype O isolates of 2015 and those of 2016 and 2017. The serotype A isolates belonged to the A-Iran-05 lineage, with the exception of one isolate of 2016 which clustered with the African strains of G-IV. Serotype SAT2 FMDV was detected in two samples of 2017 and both were of lineage Alx-12 of topotype VII. The virus neutralisation test using sera raised against vaccine strains confirmed the serotyping of the isolates and determined the antigenic relatedness between the isolates and the currently used vaccine strains. A decrease in the neutralising antibody titre of some serotype O and A isolates could be attributed to mutation in critical amino acids in the neutralising antigenic sites. Hence, this work supports previous studies describing the significance of amino acid substitutions within the antigenic sites of the virus in antibody neutralisation and immune escape.

La fièvre aphteuse est à l'origine d'importantes pertes économiques en Égypte. Si la vaccination constitue la principale stratégie de lutte contre cette maladie, de nombreux échecs vaccinaux ont été rapportés, dus à différents facteurs. Il a été constaté par le passé que la pression immunitaire exercée par des hôtes partiellement immunisés contre la fièvre aphteuse entraînait une sélection de variants antigéniques du virus. La présente étude avait donc pour objet d'isoler et de caractériser les virus de la fièvre aphteuse présents en Égypte chez les animaux vaccinés. Les sérotypes O, A et Southern African Territories (SAT) 2 du virus de la fièvre aphteuse ont été détectés dans plusieurs gouvernorats égyptiens en 2015, 2016 et 2017. Les auteurs font état de 15 isolements réussis de souches virales appartenant à chacun des trois sérotypes. Il ressort de l'analyse phylogénétique basée sur le gène de la protéine virale 1 (PV1) que tous les isolats de sérotype O correspondaient au topotype East Africa (EA) 3. Une variation de 15 à 17 acides aminés a été observée entre les virus de sérotype O isolés en 2015 et ceux du même sérotype isolés en 2016 et en 2017. Les isolats de sérotype A appartenaient tous à la lignée A-Iran-05, à l'exception d'un isolat de 2016 qui était proche des souches africaines du lignage G-IV. Le sérotype SAT-2 du virus de la fièvre aphteuse a été détecté dans deux échantillons prélevés en 2017. Les deux souches isolées appartenaient à la lignée Alx-12 du topotype VII. La neutralisation virale utilisant des antisérums produits contre les souches vaccinales a permis de confirmer le sérotypage des souches isolées et de déterminer le degré de similitude entre les isolats et les souches vaccinales utilisées actuellement. La diminution du titre d'anticorps neutralisants dirigés contre certains isolats des sérotypes O et A est probablement imputable à une mutation d'acides aminés déterminants au sein des sites de neutralisation des antigènes. Ce travail corrobore les résultats d'études antérieures qui avaient révélé que les substitutions d'acides aminés au sein des sites antigéniques du virus peuvent avoir un rôle dans la neutralisation d'anticorps et dans l'échappement du virus au système immunitaire.

La fiebre aftosa es causante de graves pérdidas económicas en Egipto. Aunque la vacunación viene siendo la principal estrategia de lucha, se han descrito numerosos casos en los que ha resultado ineficaz, hecho que puede deberse a varios factores. Anteriormente ya se había observado que la presión inmunitaria de hospedadores parcialmente inmunizados conduce a la selección de determinadas variantes antigénicas de la fiebre aftosa. Los autores exponen un estudio encaminado a aislar y caracterizar los virus de la fiebre aftosa circulantes en los animales egipcios vacunados. En los años 2015, 2016 y 2017 se detectaron en diferentes provincias del país los serotipos víricos O, A y SAT (Southern African Territories) 2. Los autores dan cuenta del aislamiento de 15 virus de la fiebre aftosa pertenecientes a uno u otro de estos tres serotipos. El análisis filogenético basado en el gen de la proteína vírica (VP) 1 demostró que todos los virus del serotipo O aislados correspondían al topotipo EA (East Africa)-3, con diferencias localizadas en los aminoácidos 15 a 17 entre los virus aislados en 2015 y los de 2016 y 2017. Los virus del serotipo A pertenecían al linaje A-Iran-05, con la excepción de uno de los de 2016, que formaba un conglomerado con las cepas africanas del linaje G-IV. El serotipo SAT2, por su parte, estaba presente en dos muestras de 2017, pertenecientes ambas al linaje Alx-12 del topotipo VII. Empleando la prueba de neutralización vírica con sueros sensibilizados contra cepas vacunales se confirmó el serotipo de los virus aislados y se determinó el grado de parentesco antigénico entre esos virus y las cepas vacunales utilizadas actualmente. El decremento observado en el título de anticuerpos neutralizantes frente a algunos de esos virus de los serotipos O y A podría explicarse por la mutación de aminoácidos fundamentales de los sitios antigénicos neutralizantes. Este trabajo, por lo tanto, viene a corroborar anteriores estudios que señalaban la gran influencia de la sustitución de aminoácidos en los sitios antigénicos del virus en los procesos de neutralización de anticuerpos y escape inmunitario.

Rabies prevention: the role of serology in parenteral vaccination of companion animals and livestock.

Rabies virus (RABV)-specific antibodies generated in response to rabies vaccination provide the basis for the establishment of rabies protection and hence rabies control and prevention. Rabies serology is the primary and most appropriate way to determine vaccination efficacy. Various immunological methods, such as serum neutralisation, enzyme-linked immunosorbent assay, the indirect fluorescent antibody test and immunochromatographic (or lateral flow) assay can detect and measure these antibodies. These methods range from complex to simple and from highly precise to approximate. Rabies serology interpretation, cut-off levels and method limitations are important considerations that oftentimes are overlooked when evaluating the results of tests that measure the immune response to rabies vaccination or RABV antigen exposure. In addition, a meaningful result may depend on the timing of obtaining the samples. Practical issues such as the costs of testing and accessibility of test reagents or facilities play an increasingly important role in the success of rabies elimination efforts in developing areas. The discovery of new lyssaviruses in recent years means that the rabies vaccines currently in use should be evaluated to determine whether or not they confer protection against these viruses. Methods that can be adapted for the measurement of RABV-specific antibodies are needed. Whether used for diagnosis, serosurveillance, or determination of individual or group vaccine response, rabies serology has a great impact on rabies control and prevention efforts. It is critical, therefore, that not only does the method employed generate results that are applicable, but that these results are interpreted correctly. To ensure that this is the case, it is crucial to know exactly what the test was designed to measure and to understand its limitations.

L'apparition d'anticorps spécifiques contre le virus de la rage après une vaccination antirabique constitue la base de la réponse protectrice et donc du contrôle et de la prévention de la maladie. Le suivi sérologique de la rage est la méthode la plus courante et la plus appropriée pour déterminer l'efficacité de la vaccination. Plusieurs méthodes immunologiques telles que le test de séroneutralisation, l'épreuve immuno-enzymatique, le test indirect aux anticorps fluorescents et l'essai immunochromatographique (ou immuno-essai à flux latéral) permettent de détecter et de titrer ces anticorps. Ces méthodes vont des plus simples aux plus complexes avec des résultats pouvant être extrêmement précis pour certaines ou plus approximatifs pour d'autres. L'interprétation des résultats sérologiques, les valeurs seuils et les limites inhérentes à chaque méthode sont des points importants à prendre en compte mais ils sont souvent négligés au moment d'évaluer les résultats des tests visant à mesurer la réponse immune induite par la vaccination ou l'exposition à l'antigène viral. En outre, l'obtention d'un résultat pertinent dépend parfois du moment de la prise d'échantillons. Des problèmes concrets tels que le coût des analyses, la disponibilité des réactifs et l'accès aux laboratoires d'analyses ont une incidence de plus en plus déterminante sur le succès des efforts déployés dans les régions en développement pour éliminer la rage. Du fait de la découverte récente de nouveaux lyssavirus, il conviendra d'évaluer les vaccins antirabiques utilisés actuellement afin de déterminer s'ils confèrent ou non une protection contre ces virus. Il faudra disposer de méthodes susceptibles d'être adaptées pour le titrage d'anticorps spécifiques contre le virus de la rage. Qu'elle soit utilisée à des fins de diagnostic, de surveillance sérologique ou pour déterminer l'efficacité de la vaccination chez un individu ou dans un groupe, la sérologie antirabique a un impact important sur les activités de contrôle et de prévention de la rage. Il est donc essentiel que la méthode utilisée produise des résultats susceptibles d'être appliqués et surtout que ceux ci soient interprétés correctement. Pour s'assurer que tel est le cas il faut savoir exactement ce que le test est censé mesurer et bien appréhender ses limites.

Los anticuerpos específicos contra el virus de la rabia que se generan en respuesta a la vacunación antirrábica ponen los cimientos de la protección contra la enfermedad y, por ende, de su prevención y control. La serología de la rabia es el medio fundamental y más adecuado de determinar la eficacia de la vacunación. Hay varias técnicas inmunológicas que permiten detectar y cuantificar esos anticuerpos, como la de neutralización vírica, la de ensayo inmunoenzimático, la de inmunofluorescencia indirecta o la de inmunocromatografía (o flujo lateral). Estos métodos son muy dispares en cuanto a su nivel de complejidad y al grado de precisión que ofrecen. La interpretación de la serología de la rabia, los valores umbral y las limitaciones de cada método son factores importantes que a menudo se pasan por alto a la hora de valorar los resultados de las pruebas que miden la respuesta inmunitaria a la vacunación antirrábica o a la exposición a antígenos víricos. Además, la obtención de un resultado significativo depende a veces de la secuencia y el momento de la obtención de muestras. También hay cuestiones prácticas, como el coste de las técnicas o el acceso a instalaciones y reactivos de prueba, que en las zonas en desarrollo resultan cada vez más determinantes para el éxito de las campañas de eliminación de la rabia. Del descubrimiento de nuevos lisavirus en los últimos años se sigue la necesidad de evaluar las vacunas antirrábicas utilizadas actualmente para dilucidar si confieren o no protección contra esos virus. Hacen falta métodos que puedan adaptarse a la medición de anticuerpos específicos contra el virus de la rabia. Ya se utilice con fines de diagnóstico, de serovigilancia o para determinar la respuesta a la vacuna de un individuo o un grupo, la serología de la rabia tiene gran influencia en las medidas de prevención y control de la enfermedad. Por ello es absolutamente fundamental no solo emplear un método que genere resultados que sean aplicables, sino también interpretar correctamente esos resultados. Para tener la seguridad de que ello es así, es fundamental saber exactamente para qué parámetro ha sido concebida la prueba y entender las limitaciones de esta.

Production and calibration of the second batch of OIE anti-rabies positive reference serum.

The Biological Standards Commission of the World Organisation for Animal Health (OIE) oversees the preparation and validation of OIE-approved International Reference Standards for use in serological assays for detecting infectious diseases of animals or the adequacy of their immune response following vaccination against those diseases. The principal use of OIE-approved International Reference Standards is to harmonise serological testing and to promote the mutual recognition of test results for international trade. In the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, the organisation recommends the use of the OIE anti-rabies positive reference serum of dog origin to titrate serum samples in international units (IU)/ml for use in rabies serological tests. The first batch of OIE reference serum of dog origin was produced in1991 and was used internationally until the beginning of 2010. The preparation of the new batch began in 2012 and, in contrast to the previous batch, three commercial inactivated rabies vaccines based on the most frequently used vaccine strains (Pasteur Virus and Flury Low Egg Passage) were selected for the immunisation of dogs in accordance with OIE guidelines. In 2013, calibration was completed through an inter-laboratory test involving five OIE Reference Laboratories for Rabies with the Second World Health Organization (WHO) International Standard for Anti-Rabies Immunoglobulin being used as a reference standard in this calibration. After statistical analysis of the results, the consensus titre was established as 5.59 IU/ml. The technical and statistical data were submitted to the OIE for assessment. In February 2014, the OIE Biological Standards Commission adopted this serum as an OIE-approved standard reagent for rabies serology.

La Commission des normes biologiques de l'Organisation mondiale de la santé animale (OIE) supervise la préparation et la validation de réactifs internationaux de référence approuvés par l'OIE et destinés aux épreuves sérologiques ayant pour objet le diagnostic des maladies infectieuses des animaux ou le suivi de l'effet protecteur obtenu par la vaccination contre ces maladies. Les réactifs internationaux de référence approuvés par l'OIE sont principalement utilisés pour harmoniser les tests sérologiques et permettre la reconnaissance mutuelle des résultats des tests dans le cadre des échanges internationaux. Le Manuel des tests de diagnostic et des vaccins pour les animaux terrestres de l'OIE recommande d'utiliser le sérum de référence antirabique positif d'origine canine de l'OIE pour exprimer le titre des échantillons de sérum analysés en unités internationales (UI)/ml lors des épreuves sérologiques. Le premier lot de sérum de référence d'origine canine de l'OIE, produit en 1991, a été utilisé à l'échelle internationale jusqu'au début de l'année 2010. La préparation d'un nouveau lot a commencé en 2012 et, contrairement au lot précédent, trois vaccins antirabiques inactivés disponibles dans le commerce, basés sur les souches vaccinales les plus utilisées dans le monde (souche Pasteur et souche Flury Low Egg Passage) ont été choisis pour l'immunisation des chiens, conformément aux lignes directrices de l'OIE. L'étalonnage s'est achevé en 2013 lors d'un essai inter-laboratoires auquel ont participé cinq Laboratoires de référence de l'OIE pour la rage ; le second étalon international pour l'immunoglobuline antirabique de l'Organisation mondiale de la santé (OMS) a été utilisé en tant que réactif de référence pour cet étalonnage. Après analyse statistique des résultats, le titre consensuel obtenu est de 5,59 UI/ml. Les données techniques et statistiques ont été soumises à l'OIE pour évaluation. En février 2014, la Commission des normes biologiques de l'OIE a adopté ce sérum en tant qu'étalon de référence approuvé par l'OIE pour la sérologie de la rage.

La Comisión de Normas Biológicas de la Organización Mundial de Sanidad Animal (OIE) supervisa la preparación y validación de patrones de referencia internacional aprobados por la OIE para su utilización en ensayos serológicos destinados a detectar enfermedades animales infecciosas o a valorar la idoneidad de la respuesta inmunitaria de un animal al ser vacunado contra una u otra enfermedad. Dichos patrones sirven sobre todo para armonizar la realización de pruebas serológicas y promover el reconocimiento mutuo de los resultados de las pruebas con fines de comercio internacional. En su Manual de las Pruebas de Diagnóstico y de las Vacunas para los Animales Terrestres, la OIE recomienda el empleo del suero positivo antirrábico de referencia de la OIE, de origen canino, para titular muestras de suero en unidades internacionales (UI)/ml y utilizarlas en pruebas serológicas de detección de la rabia. El primer lote de suero de referencia de la OIE procedente de perros fue elaborado en 1991 y estuvo en uso a nivel internacional hasta principios de 2010. La preparación del nuevo lote dio comienzo en 2012 y, a diferencia del lote anterior, para la inmunización del perro se seleccionaron tres vacunas inactivadas comerciales basadas en las cepas vacunales utilizadas con más frecuencia (virus Pasteur y cepa Flury Low Egg Passage), de conformidad con las directrices de la OIE. En 2013 culminó el proceso de calibración con una prueba interlaboratorios en la que intervinieron cinco Laboratorios de Referencia de la OIE para la rabia. En esta calibración se utilizó como patrón de referencia el segundo patrón internacional de inmunoglobulina antirrábica de la Organización Mundial de la Salud (OMS). Tras el análisis estadístico de los resultados, el título de consenso quedó fijado en 5,59 UI/ml. Los datos técnicos y estadísticos fueron sometidos a la valoración de la OIE, cuya Comisión de Normas Biológicas, en febrero de 2014, aprobó este suero como reactivo de referencia aprobado por la OIE para pruebas serológicas de detección de la rabia.

Cross-neutralization studies with salmonid alphavirus subtype 1-6 strains: results with sera from experimental studies and natural infections.

The serological reactivity between strains of each of the six currently genetically defined subtypes of salmonid alphavirus (SAV) was examined by comparison of homologous and heterologous virus neutralization titres on sera from experimentally infected fish. With the exception of the level of SAV subtype 6 neutralization by heterologous sera, good cross-neutralization was detected between all subtypes, albeit with variation in geometric mean titres when each subtype-specific serum set was tested against the panel of virus subtypes. A similar pattern was evident with field sera, except that heterologous neutralization of the SAV6 strain was more evident. In only 23% of available pairwise comparisons was the homologous titre recorded with an experimentally derived serum fourfold or greater than the heterologous titre, and in only two instances was this difference demonstrated in both directions. No virus strains consistently met the old serology-based criteria (Sub-committee on Inter-relationships Among Catalogued Alphaviruses) to be considered separate subtypes within an alphavirus species. Only when testing with an SAV subtype-2-specific monoclonal antibody was a major difference between homologous and heterologous neutralization capacity evident. These results provide new direct or indirect information in terms of SAV classification, vaccine efficacy and the selection and validation of reagents for serological and immunological diagnostic purposes.

Development of Virus-like Particle Plant-Based Vaccines against Avian H5 and H9 Influenza A Viruses.

Avian influenza A virus (AIV) is a significant cause of mortality in poultry, causing substantial economic loss, particularly in developing countries, and has zoonotic potential. For example, highly pathogenic avian influenza (HPAI) viruses of the H5 subtype have been circulating in Egypt for around two decades. In the last decade, H5N1 viruses of clade 2.2.1 have been succeeded by the antigenically distinct H5N8 clade 2.3.4.4b viruses. Furthermore, H9N2 viruses co-circulate with the H5N8 viruses in Egyptian poultry. It is widely recognised that effective vaccination against IAV requires a close antigenic match between the vaccine and viruses circulating in the field. Therefore, approaches to develop cost-effective vaccines that can be rapidly adapted to local virus strains are required for developing countries such as Egypt. In this project, the haemagglutinin (HA) proteins of Egyptian H5 and H9 viruses were expressed by transient transfection of plants (Nicotiana benthamiana). The formation of virus-like particles (VLPs) was confirmed by transmission electron microscopy. Mice were immunised with four doses of either H5 or H9 VLPs with adjuvant. Antibody and cellular immune responses were measured against the corresponding recombinant protein using ELISA and enzyme-linked immunosorbent assay (ELISpot), respectively. Chickens were immunised with one dose of H5 VLPs, eliciting HA-specific antibodies measured by ELISA and a pseudotyped virus neutralisation test using a heterologous H5 HA. In conclusion, plant-based VLP vaccines have potential for producing an effective vaccine candidate within a short time at a relatively low cost.

Multiparametric analysis of the specific immune response against SARS-CoV-2.

BACKGROUND: SARS-CoV-2, which causes COVID-19, has killed more than 7 million people worldwide. Understanding the development of postinfectious and postvaccination immune responses is necessary for effective treatment and the introduction of appropriate antipandemic measures. OBJECTIVES: We analysed humoral and cell-mediated anti-SARS-CoV-2 immune responses to spike (S), nucleocapsid (N), membrane (M), and open reading frame (O) proteins in individuals collected up to 1.5 years after COVID-19 onset and evaluated immune memory. METHODS: Peripheral blood mononuclear cells and serum were collected from patients after COVID-19. Sampling was performed in two rounds: 3-6 months after infection and after another year. Most of the patients were vaccinated between samplings. SARS-CoV-2-seronegative donors served as controls. ELISpot assays were used to detect SARS-CoV-2-specific T and B cells using peptide pools (S, NMO) or recombinant proteins (rS, rN), respectively. A CEF peptide pool consisting of selected viral epitopes was applied to assess the antiviral T-cell response. SARS-CoV-2-specific antibodies were detected via ELISA and a surrogate virus neutralisation assay. RESULTS: We confirmed that SARS-CoV-2 infection induces the establishment of long-term memory IgG+ B cells and memory T cells. We also found that vaccination enhanced the levels of anti-S memory B and T cells. Multivariate comparison also revealed the benefit of repeated vaccination. Interestingly, the T-cell response to CEF was lower in patients than in controls. CONCLUSION: This study supports the importance of repeated vaccination for enhancing immunity and suggests a possible long-term perturbation of the overall antiviral immune response caused by SARS-CoV-2 infection.

Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021.

One consequence of the ongoing coronavirus disease pandemic was the rapid development of both in-house and commercial serological assays detecting anti-SARS-CoV-2 antibodies, in an effort to reliably detect acute and past SARS-CoV-2 infections. It is crucial to evaluate the quality of these serological tests and consequently the sero-epidemiological studies that are performed with the respective tests. Here, we describe the set-up and results of a comparative study, in which a laboratory contracted by the European Centre for Disease Prevention and Control offered a centralised service to EU/EEA Member and pre-accession Member States to test representative serum specimens with known serological results, with the gold standard technique (virus neutralisation tests) to determine the presence of neutralising antibodies. Laboratories from 12 European countries shared 719 serum specimens with the contractor laboratory. We found that in-house serological tests detecting neutralising antibodies showed the highest percent agreement, both positive and negative, with the virus neutralisation test results. Despite extensive differences in virus neutralisation protocols neutralisation titres showed a strong correlation. From the commercial assays, the best positive percent agreement was found for SARS-CoV-2 IgG (sCOVG) (Siemens - Atellica IM Analyzer). Despite lower positive percent agreement of LIAISON SARS-CoV-2 TrimericS IgG kit (Diasorin Inc.), the obtained results showed relatively good correlation with neutralisation titres. The set-up of this study allowed for high comparability between laboratories and enabled laboratories that do not have the capacity or capability to perform VNTs themselves. Given the variety of in-house protocols detecting SARS-CoV-2 specific neutralising antibodies, including the virus strain, it could be of interest to select reference isolates for SARS-CoV-2 diagnostic to be made available for interested EU Member States and pre-accession countries.

Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes.

BACKGROUND: Autochthonous transmission of Zika virus (ZIKV) has been reported in 87 countries since 2015. Although most infections are mild, there is risk of Guillain-Barré syndrome and adverse pregnancy outcomes. Vaccines are urgently needed to prevent Zika, but sufficient understanding of humoral responses and tools to assess ZIKV-specific immunity are lacking. METHODS: We developed a blockade-of-binding (BOB) ELISA using A9E and G9E, two strongly neutralising ZIKV-specific monoclonal antibodies, which do not react with dengue virus. Receiver operating characteristic curve analysis assessed A9E and G9E BOB serodiagnostic performance. BOB was then applied to samples from a surveillance cohort in Risaralda, Colombia, and phase 1 ZIKV vaccine trial samples, comparing results against traditional serologic tests. FINDINGS: In the validation sample set (n = 120), A9E BOB has a sensitivity of 93.5% (95% CI: 79.3, 98.9) and specificity 97.8 (95% CI: 92.2, 99.6). G9E BOB had a sensitivity of 100% (95% CI: 89.0, 100.0) and specificity 100% (95% CI: 95.9, 100). Serum from natural infections consistently tested positive in these assays for up to one year, and reactivity tracks well with ZIKV infection status among sera from endemic areas with complicated flavivirus exposures. Interestingly, a leading ZIKV vaccine candidate elicited minimal BOB reactivity despite generating neutralising antibody responses. INTERPRETATION: In conclusion, A9E and G9E BOB assays are sensitive and specific assays for detecting antibodies elicited by recent or remote ZIKV infections. Given the additional ability of these BOB assays to detect immune responses that target different epitopes, further development of these assays is well justified for applications including flavivirus surveillance, translational vaccinology research and as potential serologic correlates of protective immunity against Zika. FUNDING: R21 AI129532 (PI: S. Becker-Dreps), CDCBAA 2017-N-18041 (PI: A. M. de Silva), Thrasher Fund (PI: M. H. Collins), K22 AI137306 (PI: M. H. Collins).

Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific Reactivity in a Vaccination Cohort.

Virus-specific antibodies are crucial for protective immunity against SARS-CoV-2. Assessing functional antibodies through conventional or pseudotyped virus neutralisation tests (pVNT) requires high biosafety levels. Alternatively, the virus-free surrogate virus neutralisation test (sVNT) quantifies antibodies interfering with spike binding to angiotensin-converting enzyme 2. We evaluated secreted nanoluciferase-tagged spike protein fragments as diagnostic antigens in the sVNT in a vaccination cohort. Initially, spike fragments were tested in a capture enzyme immunoassay (EIA), identifying the receptor binding domain (RBD) as the optimal diagnostic antigen. The sensitivity of the in-house sVNT applying the nanoluciferase-labelled RBD equalled or surpassed that of a commercial sVNT (cPass, GenScript Diagnostics) and an in-house pVNT four weeks after the first vaccination (98% vs. 94% and 72%, respectively), reaching 100% in all assays four weeks after the second and third vaccinations. When testing serum reactivity with Omicron BA.1 spike, the sVNT and pVNT displayed superior discrimination between wild-type- and variant-specific serum reactivity compared to a capture EIA. This was most pronounced after the first and second vaccinations, with the third vaccination resulting in robust, cross-reactive BA.1 construct detection. In conclusion, utilising nanoluciferase-labelled antigens permits the quantification of SARS-CoV-2-specific inhibitory antibodies. Designed as flexible modular systems, the assays can be readily adjusted for monitoring vaccine efficacy.

Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants.

BACKGROUND: Although the number of measles cases declined globally in response to anti-measles immunisation campaigns, measles has re-emerged. A review of current vaccination policies is required to improve measles elimination strategies. METHODS: A pseudotype-based virus neutralisation assay (PVNA) was used to measure neutralising antibody titres in serum samples collected from Thai infants at six timepoints before and after two-doses of MMR (1&2) vaccination (ClinicalTrials.gov no. NCT02408926). Vesicular stomatitis virus (VSV) luciferase pseudotypes bearing the haemaglutinin (H) and fusion (F) glycoproteins of measles virus (MeV) were prepared. Serial dilutions of serum samples were incubated with VSV (MeV) pseudotypes and plated onto HEK293-human SLAM1 cells; the neutralising antibody titre was defined as the dilution resulting in 90% reduction in luciferase activity. RESULTS: Neutralising antibody titres in infants born with high levels of maternal immunity (H group) persisted at the time of the first MMR vaccination, and those infants did not respond effectively by developing protective titres. In contrast, infants with lower maternal immunity (L group) developed protective titres of antibody following vaccination. Responses to the second MMR vaccination were significantly higher (P = 0.0171, Wilcoxon signed-rank test) in the H group. The observed correlation between anti-MeV IgG level and neutralising antibody titre in Thai infants indicates the possibility of using rapid IgG testing as a surrogate measure for neutralising activity to define clinical protection levels within populations. CONCLUSION: These results demonstrate that varying the timing of the first MMR immunisation according to the level of acquired maternal immunity could increase vaccination immunogenicity and hence accelerate measles eradication.

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.

BACKGROUND: Rapid spread of the omicron SARS-CoV-2 variant despite extensive vaccination suggests immune escape. The neutralising ability of different vaccines alone or with natural SARS-CoV-2 infection against omicron is not well-known. METHODS: In this cross-sectional study, we tested the ability of vaccine and natural infection induced antibodies to neutralise omicron variant in a live virus neutralisation assay in four groups of individuals: (i) ChAdOx1 nCoV-19 vaccination, (ii) ChAdOx1 nCoV-19 vaccination plus prior SARS-CoV-2 infection, (iii) vaccination with inactivated virus vaccine (BBV152), and (iv) BBV152 vaccination plus prior SARS-CoV-2 infection. Primary outcome was fold-change in virus neutralisation titre against omicron compared with ancestral virus. FINDINGS: We included 80 subjects. The geometric mean titre (GMT) of the 50% focus reduction neutralisation test (FRNT50) was 380·4 (95% CI: 221·1, 654·7) against the ancestral virus with BBV152 vaccination and 379·3 (95% CI: 185·6, 775·2) with ChAdOx1 nCov-19 vaccination alone. GMT for vaccination plus infection groups were 806·1 (95% CI: 478·5, 1357·8) and 1526·2 (95% CI: 853·2, 2730·0), respectively. Against omicron variant, only 5 out of 20 in both BBV152 and ChAdOx1 nCoV-19 vaccine only groups, 6 out of 20 in BBV152 plus prior SARS-CoV-2 infection group, and 9 out of 20 in ChAdOx1 nCoV-19 plus prior SARS-CoV-2 infection group exhibited neutralisation titres above the lower limit of quantification (1:20) suggesting better neutralisation with prior infection. A reduction of 26·6 and 25·7 fold in FRNT50 titres against Omicron compared to ancestral SARS-CoV-2 strain was observed for individuals without prior SARS-CoV-2 infection vaccinated with BBV152 and ChAdOx1 nCoV-19, respectively. The corresponding reduction was 57·1 and 58·1 fold, respectively, for vaccinated individuals with prior infection. The 50% neutralisation titre against omicron demonstrated moderate correlation with serum anti-RBD IgG levels [Spearman r: 0·58 (0·41, 0·71)]. INTERPRETATION: Significant reduction in the neutralising ability of both vaccine-induced and vaccine plus infection-induced antibodies was observed for omicron variant which might explain immune escape. FUNDING: Department of Biotechnology, India; Bill & Melinda Gates Foundation, USA.

Neutralising Antibodies against Enterovirus and Parechovirus in IVIG Reflect General Circulation: A Tool for Sero-Surveillance.

Non-polio enteroviruses (NPEV) and parechoviruses (PeV) are widespread pathogens that cause significant morbidity. Surveillance is based on culturing or genotyping of virus strains found in clinical samples. Sero-surveillance, by measuring neutralising antibodies (nAb) through virus neutralisation assays (VNA), could provide additional information as it offers a more comprehensive overview of exposure to circulating types in the general population. In our study we evaluated Intravenous immunoglobulins (IVIG) to generate sero-surveillance data. We performed VNA of nineteen NPEV and PeV with Dutch IVIG batches from two different time points (2010 and 2017) and an IVIG batch from Vietnam (2011). We compared our findings with geno- and sero-surveillance data and evaluated changes over time and between the two countries. Our findings show a good correlation with what is known from geno-surveillance data. The highest nAb titres were found against strains from Enterovirus B, while we did not observe nAb titres against strains belonging to Enterovirus C. In conclusion, we demonstrated that sero-surveillance by means of IVIG can be used to obtain insight into circulation of EV and PeV genotypes. This is of particular interest for public health, to evaluate changes over time and population susceptibility to emerging genotypes.

Presence of antibodies to Crimean Congo haemorrhagic fever virus in sheep in Tunisia, North Africa.

Crimean-Congo haemorrhagic fever (CCHF) is an emerging tick-borne disease causing severe and fatal haemorrhagic syndrome in humans. Hyalomma spp. ticks are the primary vectors and sheep are important CCHF virus (CCHFV)-amplifying hosts. In this study, blood samples and ticks collected in October 2019 from 270 sheep from 15 farms across Tunisia constituted the main research material. Moreover, the sera of the same animals taken at different periods between 2018 and 2019 were also used to obtain comparative results. To investigate the presence of anti-CCHFV antibodies in sheep, all sera were tested using ELISA. Reactive sera were further characterised by a virus neutralisation test (VNT). Overall, one out of the 270 tested sheep was both ELISA- and strongly VNT-positive to CCHFV. Another two sheep were borderline ELISA-positive but did not exhibit neutralising antibodies. Ninety-one ticks were collected from all sampled sheep, of which 34 (37.4%) belonged to Hyalomma spp. This is the first report of anti-CCHFV antibodies in sheep from Tunisia. Both the results of this study and the recent CCHFV detection in ticks collected from camels in southern Tunisia indicate that further studies are needed to determine the competent tick vector in the country and to characterise the epidemiological cycle of CCHFV.

Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes.

This protocol details a rapid and reliable method for the production and titration of high-titre viral pseudotype particles with the SARS-CoV-2 spike protein (and D614G or other variants of concern, VOC) on a lentiviral vector core, and use for neutralisation assays in target cells expressing angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). It additionally provides detailed instructions on substituting in new spike variants via gene cloning, lyophilisation and storage/shipping considerations for wide deployment potential. Results obtained with this protocol show that SARS-CoV-2 pseudotypes can be produced at equivalent titres to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) pseudotypes, neutralised by human convalescent plasma and monoclonal antibodies, and stored at a range of laboratory temperatures and lyophilised for distribution and subsequent application.

The selection of naturally stable candidate foot-and-mouth disease virus vaccine strains for East Africa.

Foot-and-mouth disease (FMD) is a global burden on the livestock industry. The causative agent, FMD virus (FMDV), is highly infectious and exists in seven distinct serotypes. Vaccination remains the most effective control strategy in endemic regions and current FMD vaccines are made from inactivated preparations of whole virus. The inherent instability of FMDV and the emergence of new strains presents challenges to efficacious vaccine development. Currently, vaccines available in East Africa are comprised of relatively historic strains with unreported stabilities. As an initial step to produce an improved multivalent FMD vaccine we have identified naturally stable East African FMDV strains for each of the A, O, SAT1 and SAT2 serotypes and investigated their potential for protecting ruminants against strains that have recently circulated in East Africa. Interestingly, high diversity in stability between and within serotypes was observed, and in comparison to non-African A serotype viruses reported to date, the East African strains tested in this study are less stable. Candidate vaccine strains were adapted to propagation in BHK-21 cells with minimal capsid changes and used to generate vaccinate sera that effectively neutralised a panel of FMDV strains selected to improve FMD vaccines used in East Africa. This work highlights the importance of combining tools to predict and assess FMDV vaccine stability, with cell culture adaptation and serological tests in the development of FMD vaccines.